CAR T Cells in Lung Cancer: Targeting Tumor-Associated Antigens to Revolutionize Immunotherapy

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155947 - 155947

Published: March 1, 2025

Language: Английский

---

Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: March 22, 2023

Whereas the contribution of tumor microenvironment to profound immune suppression glioblastoma (GBM) is clear, tumor-cell intrinsic mechanisms that regulate resistance CD8 T cell mediated killing are less understood. Kinases potentially druggable targets drive progression and might influence response. Here, we perform an in vivo CRISPR screen identify glioma kinases contribute evasion cells from recognition. The reveals checkpoint kinase 2 (Chek2) be most important contributing escape T-cell Genetic depletion or pharmacological inhibition Chek2 with blood-brain-barrier permeable drugs currently being evaluated clinical trials, combination PD-1 PD-L1 blockade, lead survival benefit multiple preclinical models. Mechanistically, loss enhances antigen presentation, STING pathway activation expression mouse gliomas. Analysis human GBMs demonstrates inversely associated presentation activation. Collectively, these results support as a promising target for enhancement response blockade therapy GBM.

Language: Английский

---

Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Nov. 15, 2023

At present, cancer is the largest culprit that endangers human health. The current treatment options for mainly include surgical resection, adjuvant radiotherapy and chemotherapy, but their therapeutic effects long-term prognosis are unsatisfactory. Immunotherapy an emerging therapy has completely transformed landscape of advanced cancers, tried to occupy a place in neoadjuvant resectable tumors. However, not all patients respond immunotherapy due immunological molecular features Traditional Chinese Medicine (TCM) provides new perspective considered have potential as promising anti-tumor drugs considering its immunoregulatory properties. This review concludes commonly used TCM monomers compounds from immune regulatory pathways, aiming clearly introduce basic mechanisms boosting several common TCM. In addition, we also summarized closed ongoing trials presented prospects future development. Due significant role non-small cell lung (NSCLC), combined with should be emphasized NSCLC.

Language: Английский

---

Recent Advances in Cancer Immunotherapy Delivery Modalities

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(2), P. 504 - 504

Published: Feb. 2, 2023

Immunotherapy is crucial in fighting cancer and achieving successful remission. Many novel strategies have recently developed, but there are still some obstacles to overcome before we can effectively attack the cells decimate environment by inducing a cascade of immune responses. To successfully demonstrate antitumor activity, must be delivered exposed system. Such cutting-edge technology necessitates meticulously designed delivery methods with no loss or superior homing onto environments, as well high therapeutic efficacy fewer adverse events. In this paper, discuss recent advances immunotherapy techniques, their future prospects.

Language: Английский

---

Highly proliferative and hypodifferentiated CAR-T cells targeting B7–H3 enhance antitumor activity against ovarian and triple-negative breast cancers

Cancer Letters, Journal Year: 2023, Volume and Issue: 572, P. 216355 - 216355

Published: Aug. 18, 2023

Language: Английский

---